Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) General Counsel Sells $20,275.64 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) General Counsel David I. Sandoval sold 4,466 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $4.54, for a total value of $20,275.64. Following the completion of the sale, the general counsel now owns 41,447 shares of the company’s stock, valued at approximately $188,169.38. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

MaxCyte Price Performance

Shares of MXCT stock opened at $4.75 on Friday. MaxCyte, Inc. has a twelve month low of $3.16 and a twelve month high of $5.32. The company’s 50-day moving average price is $3.96 and its 200-day moving average price is $4.03.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The company had revenue of $8.16 million for the quarter, compared to analyst estimates of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same period in the previous year, the business posted ($0.11) EPS. Equities research analysts forecast that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Mudita Advisors LLP raised its position in MaxCyte by 5.6% in the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock valued at $12,267,000 after purchasing an additional 167,101 shares during the period. Geode Capital Management LLC grew its holdings in shares of MaxCyte by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after purchasing an additional 47,960 shares during the period. State Street Corp increased its position in shares of MaxCyte by 5.1% during the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company’s stock worth $8,827,000 after purchasing an additional 111,066 shares during the last quarter. River Global Investors LLP raised its holdings in MaxCyte by 4.7% in the 3rd quarter. River Global Investors LLP now owns 2,062,562 shares of the company’s stock valued at $8,034,000 after buying an additional 93,340 shares during the period. Finally, ArrowMark Colorado Holdings LLC lifted its position in MaxCyte by 13.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock valued at $5,426,000 after buying an additional 169,250 shares during the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.